Business
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025 IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today repo
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"image","alt":"Eledon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Eledon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fe3DFQlar3TdaQ4TB5I5xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9","width":300,"height":76}},"lazy":false},{"type":"text","content":"On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025","length":112,"tagName":"p"},{"type":"text","content":"Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital","length":183,"tagName":"p"},{"type":"text","content":"Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025","length":88,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2025 operating and financial results and reviewed recent business highlights.","length":214,"tagName":"p"},{"type":"text","content":"“We continue to work diligently towards our goal of transforming the transplant treatment landscape and remain encouraged by the growing body of evidence supporting tegoprubart as a potential novel immunosuppression therapy to better protect transplanted organs,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “The second half of the year is positioned to be a time of significant progress for Eledon, with multiple updates planned from our tegoprubart studies in kidney transplantation, beginning with new data from our open-label Phase 1b this summer. In addition, we remain on track to report topline results from the Phase 2 BESTOW trial in the fourth quarter of 2025, which we believe has the potential to demonstrate the superiority of tegoprubart over standard of care, as measured by estimated glomerular filtration rate (eGFR).”","length":862,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Business Highlights","length":42,"tagName":"p"},{"type":"list",...